A Phase 2 interventional study of XEN1101 and Placebo in Major Depressive Disorder, sponsored by James Murrough. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by James Murrough · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 702nd largest by enrollment of the 1,323 interventional ones that give a count, is one of 72 that started in 2021, is one of 271 in phase 2, and was the 1,118th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
University of Kentucky · Sites in United States
Ages 18–75
Eli Lilly and Company · Sites in United States, Bulgaria, Hungary and 5 more countries
Ages 18–75
Alkermes, Inc. · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 72 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 585 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
James Murrough is the lead sponsor of 9 studies on the registry; none are open to participants now.
James Murrough has 6 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
98 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
Drug: XEN1101
Subjects will take a matching placebo daily for eight weeks.
Drug: Placebo
two 10 mg capsules
matching placebo
Change in Activation Within the Reward Circuit by fMRI
The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by BOLD signal with fMRI during an Incentive Flanker Task.
Time frame: Baseline (week 0), End of treatment (week 8)
Change in Montgomery-Åsberg Depression Rating Scale Score
The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
Time frame: Baseline (week 0), End of treatment (week 8)
Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score
The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
Time frame: Baseline (week 0), End of treatment (week 8)
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
Time frame: Baseline (week 0), End of treatment (week 8)
Change in Temporal Experience of Pleasure Scale
The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items (subscale from 10-60) and consummatory pleasure and is derived of 8 items (subscale from 8-48). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.
Time frame: Baseline (week 0), End of treatment (week 8)
Change in Clinical Global Impression Scale
This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". Improvement is rated on a 1-7 scale where 1 is "Very Much Improved", 2 is "Much Improved", 3 is "Minimally Improved", 4 is "No Chang"e, 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse" The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".
Time frame: Baseline (week 0), End of treatment (week 8)
| Milestone | XEN1101 | Placebo |
|---|---|---|
| Started | 29 | 31 |
| Completed | 23 | 27 |
| Not completed | 6 | 4 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Far commute to clinical center | 1 | 0 |
The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by BOLD signal with fMRI during an Incentive Flanker Task.
| BOLD signal | XEN1101 | Placebo |
|---|---|---|
| Change in Activation Within the Reward Circuit by fMRI | -0.11 ± 0.11 | -0.04 ± 0.10 |
The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
| score on a scale | XEN1101 | Placebo |
|---|---|---|
| Change in Montgomery-Åsberg Depression Rating Scale Score | -13.01 ± 1.55 | -11.01 ± 1.50 |
The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
| score on a scale | XEN1101 | Placebo |
|---|---|---|
| Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score | -4.79 ± 0.81 | -6.61 ± 0.78 |
The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
| score on a scale | XEN1101 | Placebo |
|---|---|---|
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) | -5.93 ± 1.22 | -4.24 ± 1.18 |
The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items (subscale from 10-60) and consummatory pleasure and is derived of 8 items (subscale from 8-48). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.
| score on a scale | XEN1101 | Placebo |
|---|---|---|
| AP - Anticipatory pleasure | 4.61 ± 1.19 | 0.65 ± 1.15 |
| CP - Consummatory pleasure | 3.05 ± 0.86 | 0.61 ± 0.83 |
This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". Improvement is rated on a 1-7 scale where 1 is "Very Much Improved", 2 is "Much Improved", 3 is "Minimally Improved", 4 is "No Chang"e, 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse" The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".
| score on a scale | XEN1101 | Placebo |
|---|---|---|
| Severity | -1.31 ± 0.19 | -1.31 ± 0.19 |
| Improvement | -1.70 ± 0.23 | -1.34 ± 0.22 |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XEN1101 | 0/29 (0%) | 1/29 (3.4%) | 27/29 (93.1%) |
| Placebo | 0/31 (0%) | 0/31 (0%) | 25/31 (80.6%) |
| Event | XEN1101 | Placebo |
|---|---|---|
| FaintingMetabolism and nutrition disorders | 1/29 | 0/31 |
| Event | XEN1101 | Placebo |
|---|---|---|
| DizzinessNervous System Disorders | 11/29 | 3/31 |
| ConfusionNervous System Disorders | 6/29 | 0/31 |
| IncoordinationNervous System Disorders | 6/29 | 1/31 |
| HeadacheNervous System Disorders | 3/29 | 5/31 |
| FatigueGeneral Disorders | 4/29 | 3/31 |
| DrowsinessNervous System Disorders | 4/29 | 4/31 |
| Visual hallucinationsPsychiatric Disorders | 4/29 | 0/31 |
| Blurred VisionEye Disorders | 3/29 | 0/31 |
| Eye floatersEye Disorders | 3/29 | 0/31 |
| Impairment of attentionNervous System Disorders | 3/29 | 0/31 |
| Age, Continuous(years) | XEN1101 | Placebo | Total |
|---|---|---|---|
| Mean | 39.7 ± 13.2 | 36.5 ± 12.3 | 38.1 ± 12.7 |
| Sex: Female, Male(Participants) | XEN1101 | Placebo | Total |
|---|---|---|---|
| Female | 19 | 21 | 40 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | XEN1101 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 22 | 23 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | XEN1101 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 5 | 4 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 12 |
| White | 14 | 14 | 28 |
| More than one race | 2 | 5 | 7 |
| Unknown or Not Reported | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Immediately following publication. No end date.
Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Any purpose. Other NDCT Database
Data sharing details ↗ · nda.nih.gov
Ran from Oct 2021 to primary completion in Oct 2024, 35 months.
Results were first posted in Nov 2026, 2 years 1 month after primary completion.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 35 months is close to that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XEN1101
James Murrough